Autopsy report · NCT00272415
A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma
Cause of deathNo reason given
Life of this trial
- Registered 3 months after it had already started.
- 39 participants planned (an estimate, not an actual count).
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Genentech, Inc.
- Sponsor type
- Industry
- Conditions
- Melanoma
- Interventions
- INO-1001; temozolomide
- Participants
- 39 (planned, not actual)
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.